GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (XTER:MDG1) » Definitions » Price-to-Funds-From-Operations

Medigene AG (XTER:MDG1) Price-to-Funds-From-Operations : (As of May. 08, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Medigene AG Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Medigene AG (XTER:MDG1) Business Description

Industry
Traded in Other Exchanges
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.